NCT07548177
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 12 months later.
See at-risk trials from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Nov 2027 to Dec 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 68 words
- Study completion pushed from Nov 2028 to Jun 2029
- Secondary endpoints: details revised at 5 of 15 entries
- Site details revised at 2 of 15 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Objective response rate (IRC assessment)
Timeframe: The period from baseline to the end of the trial is expected to be 32 months.
Secondary (15)
Disease control rate (IRC assessment)
Duration of remission (IRC assessment)
Progression-free survival (IRC assessment)
12-month progression-free survival rate (IRC assessment)
24-month progression-free survival rate (IRC assessment)
Show 10 moreShow less
36-month progression-free survival rate (IRC assessment)
Objective response rate (Researcher Evaluation)
Disease control rate(Researcher Evaluation)
Duration of remission(Researcher Evaluation)
Progression-free survival (Researcher Evaluation)
The 12-month progression-free survival rate(Researcher Evaluation)
24-month progression-free survival rate(Researcher Evaluation)
36-month progression-free survival rate (Researcher Evaluation)
Overall survival
Numbers of subject with the incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators
Arms and interventions
Benmelstobart injection+Anlotinib Hydrochloride CapsulesExperimental
Benmelstobart injection combined with Anlotinib hydrochloride capsules, with a 21-day cycle.
Drugs: Benmelstobart injection combined with Anlotinib hydrochloride capsule
Sites
15 sites in 1 country